Sarepta Recent News
2 Opposing Views On The Future Of Sarepta
A Timeline Of PTC Therapeutics' Translarna Journey
3 Reasons 2017 Launch Expectations For Sarepta's EXONDYS 51 Are 'Too High'
Sarepta Shares Fall After Anthem Blue Cross Finds Issue With Eteplirsen
DMD Deal With Summit Is 'Low Risk, High Reward' For Sarepta
Sarepta Prices Newly-Approved DMD Drug, Cowen Upgrades Stock To Outperform
Sarepta Analysts Turn Bullish After Duchenne Muscular Dystrophy Drug Eteplirsen Gets Approval
Sarepta's Eteplirsen Receives Accelerated FDA Approval, Shares Soar 80%
Why Did Sarepta Therapeutics Plunge 20%?
Sarepta Therapeutics Surges 20% On No News
Sarepta Spikes 20%, Feuerstein Says Company Can Win FDA Drug Approval
The Street's Feuerstein Breaks Down Sarepta's 40% Plunge
Sarepta Therapeutics Gives Up Gains Following Notable Tweet
Investors Rewarded With Treats, Not Tricks, As Dow And S&P Close At Record Highs
Barron's Recap: Sunny Skies For Home Depot
Market Wrap For January 16: Markets End Two Day Winning Streak